dabigatran우선순위 낮음근거 검토리뷰
LITERATURE DETAIL · PMID 42630602
The use of direct oral anticoagulants in children with congenital and acquired heart disease.
The use of direct oral anticoagulants in children with congenital and acquired heart disease.
- 저자
- Eman Abdelghani, Mehul Thakkar, Jessica Berthiaume, Sanjay Ahuja
- 저널
- Frontiers in cardiovascular medicine
- 공개일
- 2026
- 연구 유형
- 리뷰
- DOI
- 10.3389/fcvm.2026.1920897
문헌 요약
Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor, dabigatran, and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), represent a significant advancement in pediatric anticoagulation therapy. Following U.S. FDA approvals for dabigatran and rivaroxaban in 2021 and apixaban in 2025, DOACs are now available for venous throm…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.